best glp-1 for Weight Loss: Oral vs Injectable Semaglutide, Side Effects, and Long-Term Tolerance Personalized GLP-1 Prescriptions

Real-world data show early discontinuation of GLP-1 therapy is linked to higher risks of coronary artery disease and heart failure.

They're not the same medication

Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)

However, innovations in drug delivery have sparked interest in alternatives like the GLP-1 patch

Millions of people started taking GLP-1 Drugs (Semaglutide or Tirzepatide) after the trials ended and drugs reached the market